Molecular and pharmacological (EGFRi, MEKi) characterisation of a colorectal cancer (CRC) cell line panel to evaluate cellular phenotype and efficacy of targeted therapies in CRC

被引：0
|
作者：
Chresta, Christine M. [1 ]
Runswick, Sarah [1 ]
Beran, Garry [1 ]
Dayenport, Sara [1 ]
Callis, Rowena [1 ]
Wilkinson, Robert W. [1 ]
机构：
[1] AstraZeneca R&D, Macclesfield, Cheshire, England
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-5365
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5365
引用
收藏
页数：1
相关论文
共 4 条
  • [1] Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
    Stintzing, S.
    Wirapati, P.
    Lenz, H. J.
    Neureiter, D.
    von Weikersthal, L. Fischer
    Decker, T.
    Kiani, A.
    Kaiser, F.
    Al-Batran, S.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Moehler, M.
    Scheithauer, W.
    Held, S.
    Modest, D. P.
    Jung, A.
    Kirchner, T.
    Aderka, D.
    Tejpar, S.
    Heinemann, V
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1796 - 1803
  • [2] Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing, Sebastian
    Wirapati, Pratyaksha
    Lenz, Heinz -Josef
    Neureiter, Daniel
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Kahl, Christoph
    Kullmann, Frank
    Moehler, Markus H.
    Scheithauer, Werner
    Held, Swantje
    Modest, Dominik Paul
    Jung, Andreas
    Kirchner, Thomas
    Tejpar, Sabine
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE-3 (AIO KRK-0306) trial
    Stintzing, S.
    Lenz, H. -J.
    Neureiter, D.
    von Weikersthal, L. F.
    Al-Batran, S. -E.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Vehling-Kaiser, U.
    Moehler, M.
    Scheithauer, W.
    Held, S.
    Modest, D. P.
    Jung, A.
    Kirchner, T.
    Wirapati, P.
    Tejpar, S.
    Heinemann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 8 - 9
  • [4] A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC).
    Baselga, J.
    Schöffski, P.
    Rojo, F.
    Dumez, H.
    Ramos, F. J.
    Macarulla, T.
    Cajal, R.
    Kisker, O.
    Van Oosterom, A.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 122S - 122S
1